Latest Commercialisation Strategy News

Papyrus Australia reached a key production milestone by delivering 200 biodegradable Collar Keeper® samples to TBS Mining Solutions, confirming its manufacturing scalability. The company’s May cash flow shows a steady funding runway amid ongoing R&D and commercialisation efforts.

GCM Corporation has inked a binding 24-month joint development agreement with Shenzhen Wanwei Heat Conduction Technology (ALVC) to co-develop a hybrid thermal management product combining vapour chamber and VHD heat sink technologies.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Li-S Energy has secured ISO 9001:2015 certification for its lithium foil production in Geelong and completed its first commercial shipment to a leading Australian battery research institution, marking a key step in establishing a sovereign lithium foil supply chain.

Pure Resources and Rice University have secured 'Awardable' status on the DARPA ERIS Marketplace for their advanced Carbon Nanotube Fibre 3D thermal management technology, positioning them for potential US Department of Defense contracts.

Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

LTR Pharma has confirmed it disclosed a binding US commercialisation agreement for ROXUS promptly after signing, responding to ASX scrutiny over pre-announcement trading activity.

dorsaVi has raised $500,000 through the exercise of 25 million unlisted options by key shareholders, reinforcing confidence in its advanced AI and neuromorphic semiconductor projects. The capital will accelerate development of its 22nm node technology targeting medical and industrial robotics markets.

PMET Resources has endorsed NRW Holdings’ ALi® atmospheric leach process for producing battery-grade lithium carbonate, highlighting its economic and environmental advantages. NRW is advancing commercialisation with ongoing testing and development plans.

Iondrive Limited’s proprietary IONSolv™ process has independently achieved a 93.5% recovery rate for dysprosium from US commercial e-waste, vastly outperforming previous techno-economic assumptions and extending its rare earth extraction capabilities into heavy rare earths.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.